Beurteilung des Therapieansprechens mit PSMA-PET

Zusammenfassung

Bei Patienten mit metastasiertem Prostatakrebs wird das Ansprechen auf die Behandlung derzeit überwiegend mit Hilfe konventioneller Bildgebung bewertet. Aktuelle Studien belegen den Wert der PSMA-Liganden-PET für die Beurteilung des Ansprechens. In aktuellen Veröffentlichungen wurden die PSMA-PET-Progressionskriterien (PPP) und die Response Evaluation Criteria In PSMA-imaging (RECIP) 1.0 für eine standardisierte Beurteilung des Ansprechens definiert. Während sich PPP auf das Auftreten neuer Läsionen oder einer biochemischen bzw. klinischen Progression stützt, bewertet RECIP neue Läsionen zusammen mit Veränderungen des gesamten PSMA-Tumorvolumens. Beide Systeme sollten zur klinischen Validierung in zukünftigen prospektiven Studien eingebunden werden.

Abstract

In patients with metastatic prostate cancer, response to treatment is currently assessed using conventional imaging criteria. Recent studies have demonstrated the value of PSMA ligand PET for response assessment. We defined the PSMA-PET Progression Criteria (PPP) and Response Evaluation Criteria In PSMA-imaging (RECIP) 1.0 previously for standardized response assessment. PPP is based on the appearance of new lesions or biochemical or clinical progression whereas RECIP evaluates new lesions together with changes in overall PSMA tumor volume. Both systems should be included in future prospective clinical trials for validation.

Schlüsselwörter

PSMA - PET/CT - Prostatakarzinom - Ansprechen

Keywords

PSMA - PET/CT - Prostate Cancer - Response

• Literatur

• 1 Jadvar H, Calais J, Fanti S. et al. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. J Nucl Med 2021;
• 2 Scher HI, Morris MJ, Stadler WM. et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016; 34: 1402-1418
• 3 Schmidkonz C, Cordes M, Goetz TI. et al. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Ann Nucl Med 2019; 33: 766-775
• 4 Ahmadzadehfar H, Azgomi K, Hauser S. et al. (68)Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with (223)Ra: Proof of Concept. J Nucl Med 2017; 58: 438-444
• 5 Seitz AK, Rauscher I, Haller B. et al. Preliminary results on response assessment using (68)Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging 2018; 45: 602-612
• 6 Plouznikoff N, Artigas C, Sideris S. et al. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients. Ann Nucl Med 2019; 33: 945-954
• 7 Grubmuller B, Rasul S, Baltzer P. et al. Response assessment using [(68) Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. Prostate 2020; 80: 74-82
• 8 Michalski K, Klein C, Brueggemann T. et al. Assessing Response to [(177)Lu]PSMA Radioligand Therapy using modified PSMA PET Progression Criteria. J Nucl Med 2021;
• 9 Gafita A, Rauscher I, Weber M. et al. Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med 2022;
• 10 Fanti S, Hadaschik B, Herrmann K. Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria. J Nucl Med 2020; 61: 678-682
• 11 Eiber M, Herrmann K, Calais J. et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med 2018; 59: 469-478
• 12 Seifert R, Emmett L, Rowe SP. et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol 2023; 83: 405-412
• 13 Gafita A, Rauscher I, Fendler WP. et al. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging 2022;
• 14 Hope TA, Truillet C, Ehman EC. et al. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med 2017; 58: 81-84
• 15 Zukotynski KA, Emmenegger U, Hotte S. et al. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted (18)F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. J Nucl Med 2021; 62: 1430-1437
• 16 Afshar-Oromieh A, Debus N, Uhrig M. et al. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging 2018; 45: 2045-2054
• 17 Fendler WP, Eiber M, Beheshti M. et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging 2023; 50: 1466-1486